Recent Updates
Recently added Catalysts
AGMB Positive Sentiment

Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook

Thursday, April 23, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Agomab Therapeutics NV has reported its financial results for the year ending December 31, 2025, highlighting a solid cash position of €116.5 million. The company also confirmed its positive outlook for 2026, indicating confidence in its future operations and strategic direction. This announcement reflects Agomab's commitment to addressing fibro-inflammation.
Price reaction · baseline $10.55 (2026-04-22 close) · hit pre-market · 1 other AGMB headline(s) in the window, move may be shared
day 0 close
+1.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Agomab has a strong cash position with €116.5 million.
  • The company has confirmed its outlook for 2026.
  • Focus on fibro-inflammation indicates a specialized therapeutic area.

Full Press Release Details

Antwerp, Belgium, April 23, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today reported financial results for the full year period ended December 31, 2025, and confirmed its outlook for 2026.
— Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of …

Frequently Asked Questions

What were Agomab's cash investments at the end of 2025?

Agomab reported cash and cash investments of €116.5 million at the end of 2025.

What is Agomab's outlook for 2026?

Agomab has confirmed a positive outlook for 2026.

What is Agomab's focus area?

Agomab focuses on fibro-inflammation as its therapeutic area.

ShareAdd on Google
Tags: AGMB Viatris Investor Conferences Healthcare Agomab fibro-inflammation financial results 2026 outlook
Last updated: Apr 23, 2026

Biotech snapshot

Lead asset
AGMB-129Phase 2
Fibrostenotic Crohn's Disease →